Basic information
- Name:
Codeine phosphate
- CAS No.:
52-28-8
- Molecular Structure:

- Formula:
- C18H21NO3•H3O4P
- Molecular Weight:
- 397.36
- Synonyms:
- Codeine phosphate anhydrous;Morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-, phosphate (1:1);Morphinan-6-ol,7,8-didehydro-4,5-epoxy-3- methoxy-17-methyl-,(5R,6R)-,phosphate (1:1) (salt);Tricodein;Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-, phosphate (1:1) (salt);UNII-GSL05Y1MN6;
- EINECS:
- 200-137-8
- Melting Point:
- 238-240 °C
- Boiling Point:
- 462 °C at 760 mmHg
- Flash Point:
- 233.2 °C
- Solubility:
- Soluble in water
- Appearance:
- White to off-white solid
Famous Chemical Enterprises
-
Livzon -
Total -
Shell -
Dupont -
Exxonmobil -
Akzonobel -
Basf -
Bayer -
BP
Please post your buying leads,so that our qualified suppliers will soon
contact you!
*Required Fields
History
1、Codeine can be extracted from opium, most codeine is synthesized from morphine through the process of O-methylation. It was first isolated in 1832 in France by Jean-Pierre Robiquet.
2、In late 1973, researchers were tasked with and quickly succeeded in finding a way to synthesize codeine and its derivatives and precursors from scratch from petroleum or coal tar using a process developed at the United States' National Institutes of Health.
3、Numerous codeine salts have been prepared since the drug was discovered.
Consensus Reports
Specification
The Codeine phosphate with CAS registry number of 52-28-8 is also known as Codeine phosphate anhydrous. The systematic name is (5α,6α)-3-Methoxy-17-methyl-7,8-didehydro-4,5-epoxymorphinan-6-ol phosphate (salt). It belongs to product categories of Intermediates & Fine Chemicals; Pharmaceuticals. Its EINECS registry number is 200-137-8. In addition, the formula is C18H21NO3•H3O4P and the molecular weight is 397.36. This chemical is a white to off-white solid that soluble in water. What's more, it can be used as weak narcotic analgesic, potent antitussive and controlled substance.
Physical properties about Codeine phosphate are: (1)ACD/LogP: 1.20; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): -1.41; (4)ACD/LogD (pH 7.4): 0.27; (5)ACD/BCF (pH 5.5): 1; (6)ACD/BCF (pH 7.4): 1; (7)ACD/KOC (pH 5.5): 1; (8)ACD/KOC (pH 7.4): 12.48; (9)#H bond acceptors: 4; (10)#H bond donors: 1; (11)#Freely Rotating Bonds: 2; (12)Polar Surface Area: 30.93Å2; (13)Flash Point: 233.2 °C; (14)Enthalpy of Vaporization: 76.18 kJ/mol; (15)Boiling Point: 462 °C at 760 mmHg; (16)Vapour Pressure: 2.47E-09 mmHg at 25 °C.
Uses of Codeine phosphate: it is used to produce 1-bromo-4,5a-epoxy-3-methoxy-17-methyl-morphin-7-en-6a-ol. The reaction occurs with reagent Br2 and solvent acetic acid. The yield is about 62%.

You can still convert the following datas into molecular structure:
1. Canonical SMILES: CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O.OP(=O)(O)O
2. Isomeric SMILES: CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O.OP(=O)(O)O
3. InChI: InChI=1S/C18H21NO3.H3O4P/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;1-5(2,3)4/h3-6,11-13,17,20H,7-9H2,1-2H3;(H3,1,2,3,4)/t11-,12+,13-,17-,18-;/m0./s1
4. InChIKey: WUXLCJZUUHIXFY-FFHNEAJVSA-N
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| cat | LDLo | oral | 50mg/kg (50mg/kg) | United States Patent Document. Vol. #3031377, | |
| dog | LD50 | intravenous | 97800ug/kg (97.8mg/kg) | SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD GASTROINTESTINAL: NAUSEA OR VOMITING | Oyo Yakuri. Pharmacometrics. Vol. 4, Pg. 961, 1970. |
| guinea pig | LD50 | intraperitoneal | 352mg/kg (352mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 27, Pg. 1450, 1977. | |
| guinea pig | LD50 | oral | 654mg/kg (654mg/kg) | SENSE ORGANS AND SPECIAL SENSES: MYDRIASIS (PUPILLARY DILATION): EYE LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Oyo Yakuri. Pharmacometrics. Vol. 6, Pg. 1207, 1972. |
| guinea pig | LD50 | subcutaneous | 140mg/kg (140mg/kg) | SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE | Oyo Yakuri. Pharmacometrics. Vol. 6, Pg. 1207, 1972. |
| guinea pig | LDLo | intraarterial | 1gm/kg (1000mg/kg) | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 131, Pg. 171, 1928. | |
| guinea pig | LDLo | intravenous | 117mg/kg (117mg/kg) | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 119, Pg. 205, 1959. | |
| mammal (species unspecified) | LD50 | unreported | 183mg/kg (183mg/kg) | LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Chemical and Pharmaceutical Bulletin. Vol. 20, Pg. 1699, 1972. |
| man | TDLo | oral | 5143ug/kg/5D- (5.143mg/kg) | BEHAVIORAL: SLEEP VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION | Clinical Pharmacy. Vol. 5, Pg. 15, 1986. |
| mouse | LD50 | intracrebral | 12mg/kg (12mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Journal of Pharmacology and Experimental Therapeutics. Vol. 140, Pg. 155, 1963. |
| mouse | LD50 | intramuscular | 191mg/kg (191mg/kg) | BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 190, Pg. 124, 1971. |
| mouse | LD50 | intraperitoneal | 110mg/kg (110mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 19, Pg. 1916, 1969. | |
| mouse | LD50 | intravenous | 62mg/kg (62mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Japanese Journal of Pharmacology. Vol. 17, Pg. 538, 1967. |
| mouse | LD50 | oral | 237mg/kg (237mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 128, Pg. 384, 1960. | |
| mouse | LD50 | subcutaneous | 80mg/kg (80mg/kg) | United States Patent Document. Vol. #3031377, | |
| rabbit | LDLo | oral | 100mg/kg (100mg/kg) | "Handbook of Toxicology," 4 vols., Philadelphia, W.B. Saunders Co., 1956-59Vol. 1, Pg. 72, 1955. | |
| rabbit | LDLo | subcutaneous | 40mg/kg (40mg/kg) | United States Patent Document. Vol. #3031377, | |
| rat | LD50 | intramuscular | 208mg/kg (208mg/kg) | BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 190, Pg. 124, 1971. |
| rat | LD50 | intraperitoneal | 104mg/kg (104mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Journal of Pharmacology and Experimental Therapeutics. Vol. 133, Pg. 117, 1961. |
| rat | LD50 | intravenous | 54mg/kg (54mg/kg) | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 103, Pg. 200, 1955. | |
| rat | LD50 | oral | 85mg/kg (85mg/kg) | United States Patent Document. Vol. #3163649, | |
| rat | LD50 | subcutaneous | 312mg/kg (312mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Journal of Pharmacology and Experimental Therapeutics. Vol. 154, Pg. 161, 1966. |
| women | TDLo | oral | 3600ug/kg/2D- (3.6mg/kg) | SENSE ORGANS AND SPECIAL SENSES: MIOSIS (PUPILLARY CONSTRICTION): EYE BEHAVIORAL: SLEEP VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION | Clinical Pharmacy. Vol. 5, Pg. 15, 1986. |

